PIOL
MCID: INT054
MIFTS: 45

Intraocular Lymphoma (PIOL) malady

Categories: Eye diseases, Blood diseases, Rare diseases, Cancer diseases, Immune diseases, Neuronal diseases

Aliases & Classifications for Intraocular Lymphoma

Aliases & Descriptions for Intraocular Lymphoma:

Name: Intraocular Lymphoma 38 12 52 42 14 69
Primary Intraocular Lymphoma 12 56
Primary Intraocular Non-Hodgkin Malignant Lymphoma 69
Primary Intraocular Non-Hodgkin's Lymphoma 56
Piol 56

Characteristics:

Orphanet epidemiological data:

56
primary intraocular lymphoma
Inheritance: Not applicable; Age of onset: Adult; Age of death: elderly;

Classifications:



External Ids:

Disease Ontology 12 DOID:775
MeSH 42 D064090
NCIt 47 C9184
Orphanet 56 ORPHA279904
ICD10 via Orphanet 34 C85,7
UMLS 69 C0281658

Summaries for Intraocular Lymphoma

MalaCards based summary : Intraocular Lymphoma, also known as primary intraocular lymphoma, is related to lymphoma and paramyloidosis. An important gene associated with Intraocular Lymphoma is C19orf48 (Chromosome 19 Open Reading Frame 48), and among its related pathways/superpathways are Akt Signaling and PAK Pathway. The drugs Amoxicillin and Ciprofloxacin have been mentioned in the context of this disorder. Affiliated tissues include brain, eye and b cells, and related phenotypes are hematopoietic system and immune system

Wikipedia : 71 Intraocular lymphoma is a rare malignant form of eye cancer. Intraocular lymphoma may affect the eye... more...

Related Diseases for Intraocular Lymphoma

Diseases related to Intraocular Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 46)
id Related Disease Score Top Affiliating Genes
1 lymphoma 10.7
2 paramyloidosis 10.1 CXCR4 PAX5
3 ureter inverted papilloma 10.1 C19orf48 IL10
4 al gazali sabrinathan nair syndrome 10.0 CXCL12 CXCR4
5 angiosarcoma 10.0 CXCR4 PAX5
6 xeroderma pigmentosum, group b 10.0 CXCL12 CXCR4
7 cerebral convexity meningioma 10.0 CXCR4 IL10
8 primary tubular proximal acidosis 10.0 CXCL12 PAX5
9 non-gestational choriocarcinoma 10.0 CXCR4 IL10
10 retinitis 10.0
11 multiple mitochondrial dysfunctions syndrome 10.0 IL10 PAX5
12 chronic cervicitis 9.9 CXCL12 CXCR4 CXCR5
13 granuloma inguinale 9.9 CXCL12 CXCR4 PAX5
14 anus leiomyosarcoma 9.9 CXCL12 CXCR4 IL10
15 hemophagocytic lymphohistiocytosis 9.9 CXCL12 CXCR4 PAX5
16 central nervous system leiomyosarcoma 9.9 CXCL12 CXCR4
17 central nervous system lymphoma 9.8
18 chorioretinitis 9.8
19 primary central nervous system lymphoma 9.8
20 uveitis 9.8
21 chronic venous leg ulcers 9.7 CXCL12 CXCR4 CXCR5 PAX5
22 rhabdomyosarcoma 9.7 CXCL12 CXCR4 IL10 PAX5
23 cytomegalovirus retinitis 9.7
24 choroiditis 9.7
25 panuveitis 9.7
26 cerebritis 9.5
27 endophthalmitis 9.5
28 systemic lupus erythematosus 9.5
29 cerebral lymphoma 9.5
30 temporal arteritis 9.5
31 breast lymphoma 9.5
32 reticulum cell sarcoma 9.5
33 acquired immunodeficiency syndrome 9.5
34 testicular lymphoma 9.5
35 vasculitis 9.5
36 lupus erythematosus 9.5
37 hypopyon 9.5
38 meningitis 9.5
39 sarcoma 9.5
40 orbit lymphoma 9.5
41 multifocal choroiditis 9.5
42 retinal vasculitis 9.5
43 orbital lymphoma 9.5
44 lymphomatous meningitis 9.5
45 pulmonary fibrosis, idiopathic 9.5 CXCL12 CXCR4 CXCR5 IL10 PAX5
46 islet cell tumor 9.0 ABCC1 C19orf48 CXCL12 CXCR4 CXCR5 IL10

Graphical network of the top 20 diseases related to Intraocular Lymphoma:



Diseases related to Intraocular Lymphoma

Symptoms & Phenotypes for Intraocular Lymphoma

MGI Mouse Phenotypes related to Intraocular Lymphoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.43 ABCC1 CXCL12 CXCR4 CXCR5 IL10 PAX5
2 immune system MP:0005387 9.1 CXCL12 CXCR4 CXCR5 IL10 PAX5 ABCC1

Drugs & Therapeutics for Intraocular Lymphoma

Drugs for Intraocular Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 268)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amoxicillin Approved, Vet_approved Phase 3 26787-78-0 33613 2171
2
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
3
Cefepime Approved Phase 3 88040-23-7 5479537
4
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
5
Ofloxacin Approved Phase 3 82419-36-1 4583
6
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
7
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
8
Cyclophosphamide Approved, Investigational Phase 2, Phase 3,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
9
Fludarabine Approved Phase 2, Phase 3, Phase 1 21679-14-1, 75607-67-9 30751
10
Melphalan Approved Phase 2, Phase 3,Phase 1 148-82-3 4053 460612
11
Thiotepa Approved Phase 2, Phase 3,Phase 1 52-24-4 5453
12
Ondansetron Approved Phase 3 99614-02-5 4595
13
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
14
Caspofungin Approved Phase 3,Phase 2 179463-17-3, 162808-62-0 468682 2826718
15
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
16
Busulfan Approved, Investigational Phase 2, Phase 3,Early Phase 1 55-98-1 2478
17
Carboplatin Approved Phase 2, Phase 3,Phase 1 41575-94-4 10339178 498142 38904
18
Etoposide Approved Phase 2, Phase 3,Phase 1,Early Phase 1 33419-42-0 36462
19
Ginseng Approved, Nutraceutical Phase 3 50647-08-0
20 Amoxicillin-Potassium Clavulanate Combination Phase 3
21 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
22 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
23 Anti-Infective Agents Phase 3,Phase 2,Phase 1
24 Antitubercular Agents Phase 3,Phase 2
25 beta-Lactamase Inhibitors Phase 3
26 Clavulanic Acid Phase 3
27 Cytochrome P-450 CYP1A2 Inhibitors Phase 3
28 Cytochrome P-450 Enzyme Inhibitors Phase 3,Phase 2,Phase 1
29 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Early Phase 1
30 Cephalosporins Phase 3
31 Renal Agents Phase 3,Phase 1,Phase 2
32 Analgesics Phase 3,Phase 1
33 Anesthetics Phase 3
34 Anesthetics, Dissociative Phase 3
35 Anesthetics, General Phase 3
36 Anesthetics, Intravenous Phase 3
37 Central Nervous System Depressants Phase 3,Phase 1,Phase 2
38 Excitatory Amino Acid Antagonists Phase 3,Phase 1
39 Excitatory Amino Acids Phase 3,Phase 1
40 Neurotransmitter Agents Phase 3,Phase 1
41 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
42 Antiemetics Phase 3,Phase 2,Phase 1
43 Autonomic Agents Phase 3,Phase 2,Phase 1
44 Dermatologic Agents Phase 3,Phase 2,Phase 1
45 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
46 Hormones Phase 3,Phase 2,Phase 1
47 Antifungal Agents Phase 3,Phase 2,Phase 1
48 Antiparasitic Agents Phase 3,Phase 2,Phase 1
49 Liver Extracts Phase 3,Phase 1
50 Alkylating Agents Phase 2, Phase 3,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 156)
id Name Status NCT ID Phase
1 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3
2 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3
3 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3
4 Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma Completed NCT00005590 Phase 3
5 Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer Completed NCT00053053 Phase 3
6 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3
7 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
8 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
9 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3
10 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
11 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3
12 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3
13 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
14 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3
15 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2
16 Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma Unknown status NCT00621036 Phase 2
17 Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders Unknown status NCT00008307 Phase 2
18 Methotrexate, Procarbazine, Lomustine, Dexamethasone, and Cytarabine in Treating Patients With Primary CNS Lymphoma Completed NCT00074191 Phase 2
19 Methotrexate, Cyclophosphamide, and Etoposide Phosphate Given With Osmotic Blood-Brain Barrier Disruption Plus Dexamethasone and Cytarabine in Treating Patients With Primary CNS Lymphoma Completed NCT00074178 Phase 2
20 Radiation Therapy and High-Dose Corticosteroids in Treating Older Patients With Primary CNS Non-Hodgkin's Lymphoma Completed NCT00003278 Phase 2
21 A Clinico-Pathological Study to Investigate the Possible Infective Causes of Non-Hodgkin Lymphoma of the Ocular Adnexae Completed NCT01010295 Phase 2
22 Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma Completed NCT00054639 Phase 2
23 Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors Completed NCT01326702 Phase 1, Phase 2
24 Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma Completed NCT01258998 Phase 2
25 High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma Completed NCT01177371 Phase 2
26 Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma Completed NCT01110135 Phase 2
27 Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies Completed NCT00072514 Phase 2
28 Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies Completed NCT01789255 Phase 2
29 Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00118352 Phase 2
30 Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies Completed NCT01427881 Phase 2
31 Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer Completed NCT00049504 Phase 2
32 Voriconazole in Preventing Fungal Infections in Children With Neutropenia After Chemotherapy Completed NCT00066599 Phase 2
33 Combination Chemotherapy and Bone Marrow Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome Completed NCT00002502 Phase 2
34 Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer or Hematologic Cancer Completed NCT00006225 Phase 1, Phase 2
35 Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer Completed NCT00237627 Phase 1, Phase 2
36 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00005804 Phase 2
37 Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer Completed NCT00823524 Phase 1, Phase 2
38 Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant Completed NCT00110045 Phase 2
39 Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma Completed NCT00006102 Phase 2
40 Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas Recruiting NCT02213913 Phase 1, Phase 2
41 Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies Recruiting NCT01839916 Phase 2
42 Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies Recruiting NCT01760655 Phase 2
43 Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma Recruiting NCT01609816 Phase 1, Phase 2
44 Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies Recruiting NCT01643603 Phase 1, Phase 2
45 Study of Ibrutinib in Patients With Relapsed or Refractory Primary Central Nervous Lymphoma or Intraocular Lymphoma Active, not recruiting NCT02542514 Phase 2
46 Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma Active, not recruiting NCT00867529 Phase 2
47 Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer Active, not recruiting NCT00006251 Phase 1, Phase 2
48 Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer Active, not recruiting NCT00089011 Phase 2
49 Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma Active, not recruiting NCT01011920 Phase 2
50 MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma Terminated NCT00089076 Phase 1, Phase 2

Search NIH Clinical Center for Intraocular Lymphoma

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Intraocular Lymphoma cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Intraocular Lymphoma:
Hematopoietic stem cells for treatment of hematologic malignancies
Embryonic/Adult Cultured Cells Related to Intraocular Lymphoma:
Bone marrow-derived hematopoietic stem cells

Cochrane evidence based reviews: intraocular lymphoma

Genetic Tests for Intraocular Lymphoma

Anatomical Context for Intraocular Lymphoma

MalaCards organs/tissues related to Intraocular Lymphoma:

39
Brain, Eye, B Cells, Retina, Bone, T Cells, Hypothalamus

Publications for Intraocular Lymphoma

Articles related to Intraocular Lymphoma:

(show top 50) (show all 192)
id Title Authors Year
1
Atypical presentation of primary intraocular lymphoma. ( 27716122 )
2016
2
ISOLD: A New Highly Sensitive Interleukin Score for Intraocular Lymphoma Diagnosis. ( 26948307 )
2016
3
Acute and late toxicity of bilateral orbital irradiation in the management of primary intraocular lymphoma. ( 27075636 )
2016
4
High-dose methotrexate following intravitreal methotrexate administration in preventing central nervous system involvement of primary intraocular lymphoma. ( 27412324 )
2016
5
Intraocular Lymphoma: Descriptive Data of 26 Patients Including Clinico-pathologic Features, Vitreous Findings, and Treatment Outcomes. ( 27438792 )
2016
6
Clinical outcomes of primary intraocular lymphoma patients treated with front-line systemic high-dose methotrexate and intravitreal methotrexate injection. ( 26732884 )
2016
7
Transient therapeutic effect of vitrectomy in primary intraocular lymphoma. ( 27904987 )
2016
8
Therapeutic vitrectomy for vitreal recurrence of intraocular lymphoma resistant to intravitreal methotrexate post systemic chemotherapy. ( 26458712 )
2015
9
Spectral-domain Optical Coherence Tomography Patterns in Intraocular Lymphoma. ( 25760916 )
2015
10
The Role of Chorioretinal Biopsy in the Diagnosis of Intraocular Lymphoma. ( 26344582 )
2015
11
Changes of choroidal structure after treatment for primary intraocular lymphoma: retrospective, observational case series. ( 26482033 )
2015
12
Case of Primary Intraocular Lymphoma with Extraocular Extension. ( 27171820 )
2015
13
Intraocular lymphoma in Korea: the Consortium for Improving Survival of Lymphoma (CISL) study. ( 26770952 )
2015
14
Intraocular Lymphoma Models. ( 27171354 )
2015
15
Intensive chemoimmunotherapy and bilateral globe irradiation as initial therapy for primary intraocular lymphoma. ( 26487691 )
2015
16
High-resolution genomic copy number profiling of primary intraocular lymphoma by single nucleotide polymorphism microarrays. ( 24612100 )
2014
17
Fundus autofluorescence patterns in primary intraocular lymphoma. ( 23958842 )
2014
18
Diagnostic vitrectomy for primary intraocular lymphoma: when, why, how? ( 24613891 )
2014
19
Cytologic features in vitreous preparations of patients with suspicion of intraocular lymphoma. ( 24167062 )
2014
20
Improving the cytological diagnosis of intraocular lymphoma from vitreous fluid. ( 25413989 )
2014
21
Spectral-domain optical coherence tomographic and fundus autofluorescence findings in eyes with primary intraocular lymphoma. ( 24520190 )
2014
22
Primary intraocular lymphoma. ( 24560125 )
2014
23
25-gauge transconjunctival diagnostic vitrectomy in suspected cases of intraocular lymphoma: a case series and review of the literature. ( 24967211 )
2014
24
Changes of fundus autofluorescence and spectral-domain optical coherence tomographic findings after treatment of primary intraocular lymphoma. ( 24559259 )
2014
25
Survival Outcomes of Primary Intraocular Lymphoma: A Single-institution Experience. ( 24390272 )
2014
26
The trabectome as treatment option in secondary glaucoma due to intraocular lymphoma. ( 25170980 )
2014
27
Primary intraocular lymphoma: treatment outcomes with ocular radiation therapy alone. ( 23822539 )
2013
28
A possible coincidence of cytomegalovirus retinitis and intraocular lymphoma in a patient with systemic non-Hodgkin's lymphoma. ( 23295015 )
2013
29
Unilateral retinopathy secondary to occult primary intraocular lymphoma. ( 24081663 )
2013
30
Intraocular lymphoma: a clinical perspective. ( 23196650 )
2013
31
Secondary orbital and intraocular lymphoma treated with immunochemotherapy. ( 25391121 )
2013
32
Two cases of intraocular lymphoma diagnosed by analyses of vitreous and infusion fluid. ( 23589676 )
2013
33
Cytokine profile in human eyes: contribution of a new cytokine combination for differential diagnosis between intraocular lymphoma or uveitis. ( 23405064 )
2013
34
Longitudinal spectral domain optical coherence tomography changes in eyes with intraocular lymphoma. ( 24011267 )
2013
35
Development of Chitosan and Poly-Lactic Acid (PLA) based Methotrexate (MTX) intravitreal micro-implants to treat primary intraocular lymphoma: an in-vitro study. ( 24317155 )
2013
36
Multicolor flowcytometric immunophenotyping is a valuable tool for detection of intraocular lymphoma. ( 23380473 )
2013
37
Current concepts in diagnosing and managing primary vitreoretinal (intraocular) lymphoma. ( 23449111 )
2013
38
Intraocular lymphoma after cardiac transplantation: magnetic resonance imaging findings. ( 23323042 )
2013
39
Evaluation of the reactive T-cell infiltrate in uveitis and intraocular lymphoma with flow cytometry of vitreous fluid (an American Ophthalmological Society thesis). ( 23818738 )
2012
40
Retinal optical coherence tomography manifestations of intraocular lymphoma. ( 22477623 )
2012
41
Birdshot retinochoroidopathy masquerading as intraocular lymphoma. ( 22594959 )
2012
42
The use of imaging in the diagnosis and management of intraocular lymphoma. ( 22954942 )
2012
43
Presumptive primary intraocular lymphoma presented as an intraocular mass involving the optic nerve head. ( 22071869 )
2012
44
Primary lymphoma of the ocular adnexa (orbital lymphoma) and primary intraocular lymphoma. ( 22521959 )
2012
45
Retrospective cytological study of intraocular lymphoma using vitreous and intraocular perfusion fluid. ( 22707324 )
2012
46
Primary intraocular lymphoma in a patient with systemic lupus erythematosus. ( 22552607 )
2012
47
Enucleation of painful blind eye for refractory intraocular lymphoma after dose-limiting chemotherapy and radiotherapy. ( 22450776 )
2012
48
Intensive chemotherapy with thiotepa, busulfan and cyclophosphamide and hematopoietic stem cell rescue in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma: a retrospective study of 79 cases. ( 22581000 )
2012
49
Clinical features and diagnostic significance of the intraocular fluid of 217 patients with intraocular lymphoma. ( 22661396 )
2012
50
Repeated IL-10 measurement in aqueous humor and OCT imaging are valuable tools to monitor intraocular lymphoma treated with intravitreal injections of methotrexate. ( 21755434 )
2012

Variations for Intraocular Lymphoma

Expression for Intraocular Lymphoma

Search GEO for disease gene expression data for Intraocular Lymphoma.

Pathways for Intraocular Lymphoma

GO Terms for Intraocular Lymphoma

Biological processes related to Intraocular Lymphoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.5 CXCL12 CXCR5 IL10
2 chemotaxis GO:0006935 9.33 CXCL12 CXCR4 CXCR5
3 positive regulation of endothelial cell proliferation GO:0001938 9.26 CXCL12 IL10
4 leukocyte chemotaxis GO:0030595 8.96 CXCR5 IL10
5 chemokine-mediated signaling pathway GO:0070098 8.8 CXCL12 CXCR4 CXCR5

Molecular functions related to Intraocular Lymphoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 C-X-C chemokine receptor activity GO:0016494 8.62 CXCR4 CXCR5

Sources for Intraocular Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....